TIGIT, a novel immune checkpoint therapy for melanoma

Melanoma is the most aggressive and deadliest type of skin cancer. In the last 10 years, immune checkpoint blockades (ICBs) including PD-1/PD-L1 and CTLA-4 inhibitor has been shown to be effective against melanoma. PD-1/PD-L1 and CTLA-4 inhibitors have shown varying degrees of drug resistance in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Wei, Chen, Jun, Ji, Tianlong, Cong, Xiufeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372028/
https://www.ncbi.nlm.nih.gov/pubmed/37495610
http://dx.doi.org/10.1038/s41419-023-05961-3